advertisement
Abstract #27906 Published in IGR 13-1
The impact of intraocular pressure reduction on retinal ganglion cell function measured using pattern electroretinogram in eyes receiving latanoprost 0.005% versus placebo
Sehi M; Grewal DS; Feuer WJ; Greenfield DSVision Research 2011; 51: 235-242
Purpose: To evaluate the impact of intraocular (IOP) reduction on retinal ganglion cell (RGC) function measured using pattern electroretinogram optimized for glaucoma (PERGLA) in glaucoma suspect and glaucomatous eyes receiving latanoprost 0.005% versus placebo. Methods: This was a prospective, placebo-controlled, double masked, cross-over clinical trial. One randomly selected eye of each subject meeting eligibility criteria was enrolled. At each visit, subjects underwent five diurnal measurements between 8:00. am and 4:00. pm consisting of Goldmann IOP, and PERGLA measurements. A baseline examination was performed following a 4-week washout period, and repeat examination after randomly receiving latanoprost or placebo for 4-weeks. Subjects were then crossed over to receive the alternative therapy for 4. weeks following a second washout period, and underwent repeat examination. Linear mixed-effect models were used for the analysis. Results: Sixty-eight eyes (35 glaucoma, 33 glaucoma suspect) of 68 patients (mean age 67.4 (plus or minus) 10.6. years) were enrolled. The mean IOP (mm. Hg) after latanoprost 0.005% therapy (14.9 (plus or minus) 3.8) was significantly lower than baseline (18.8 (plus or minus) 4.7, p<0.001) or placebo (18.0 (plus or minus) 4.3), with a mean reduction of -20 (plus or minus) 13%. Mean PERGLA amplitude ((mu)V) and phase ((pi)-radian) using latanoprost (0.49 (plus or minus) 0.22 and 1.71 (plus or minus) 0.22, respectively) were similar (p>0.05) to baseline (0.49 (plus or minus) 0.24 and 1.69 (plus or minus) 0.19) and placebo (0.50 (plus or minus) 0.24 and 1.72 (plus or minus) 0.23). No significant (p>0.05) diurnal variation in PERGLA amplitude was observed at baseline, or using latanoprost or placebo. Treatment with latanoprost, time of day, and IOP were not significantly (p>0.05) associated with PERGLA amplitude or phase. Conclusion: Twenty percent IOP reduction using latanoprost monotherapy is not associated with improvement in RGC function measured with PERGLA.
M. Sehi. Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Palm Beach Gardens, FL, United States. msehi@med.miami.edu
Classification:
6.7 Electro-ophthalmodiagnosis (Part of: 6 Clinical examination methods)
11.4 Prostaglandins (Part of: 11 Medical treatment)